Modeling and Simulation - PK/PD Archives | 第 20 页，共 46 页 | Certara

Publication

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

Certara2018 年 2 月 22 日

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Certara2018 年 2 月 15 日

Publication

Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker

Certara2018 年 2 月 8 日

Publication

Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial

Certara2018 年 1 月 15 日

Publication

Model-informed Drug Development for Malaria Therapeutics

Certara2018 年 1 月 6 日

On-Demand Webinar

如何在 Phoenix 中执行 C 级 IVIVC

C 级 IVIVC 研究分步指导。

Certara2017 年 12 月 13 日

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

Certara2017 年 11 月 1 日

Publication

A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies

Certara2017 年 10 月 30 日

Publication

Influence of Molecular Size on the Clearance of Antibody Fragments

Certara2017 年 10 月 1 日

White Paper

药物资产评估：提高交易的 "成功概率”

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

Certara2017 年 8 月 24 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software